share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

SEC announcement ·  Mar 12 20:44
Summary by Moomoo AI
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more